BenchSci is used by over 48,700 scientists at 16 top 20 pharma companies and more than 4,450 institutions to advance the speed, quality, and efficiency of their preclinical experiments.
The following represent typical results scientists across top pharma report while leveraging BenchSci in their daily work.
Watch a scientist describe why she likes using BenchSci and how it augments her decision-making.
Organizations that use BenchSci see a number of benefits, as outlined below. These values are averages, determined from our proprietary R&D Health Scan, which uses our machine learning technology to measure patterns of R&D efficiency and performance by analyzing reagent and model system spend data across cost centers at large pharma organizations.
BenchSci enables an organization to investigate 2 to 3 times the number of targets by reducing the time and material costs associated with project pursuits.
With BenchSci, a typical large pharma sees a decrease in reagent- and model system-related hard costs of millions per year.
BenchSci helps significantly decrease custom product orders, ~33% of which are unnecessary due to having a commercially available alternative.
By providing data at the point-of-decision, BenchSci prevents organizations from spending over 1M research hours per year on experiments that do not advance an asset.
More precise indications of impact can be derived by performing an R&D Health Scan at your organization. Results are presented and compared against like-sized pharma while offering insights across every therapeutic area, cost center, geography, vendor, and product type.